Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31098097 | 0.83 | UCHL1 (0.44) | CHRNB2CHRNA4MCHR1ALDH1A1LMNA | |
| SCHEMBL5010541 | 0.77 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2DPP4 | |
| SCHEMBL19023355 | 0.76 | CYP4F2 (0.47) | CHRNB2CHRNA4ALDH1A1CYP4A11CYP4F2 | |
| SCHEMBL31298312 | 0.75 | MCHR1 (0.41) | CHRNB2CHRNA4MCHR1ALDH1A1 | |
| SCHEMBL3658276 | 0.72 | CYP4A11 (0.38) | CHRNB2CHRNA4CYP4A11CYP4F2SCD | |
| SCHEMBL16828675 | 0.71 | IRAK4 (0.34) | CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL2656329 | 0.69 | CHRNB2 (0.47) | CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL4095836 | 0.69 | CHRNB2 (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL16758032 | 0.68 | CHRNB2 (0.51) | CHRNB2CHRNA4CYP4A11CYP4F2 | |
| SCHEMBL22663477 | 0.68 | CHRNB2 (0.45) | CHRNB2CHRNA4MCHR1CYP4A11CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3891149-B1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-20220135557-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135557-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | RET, REL, SLC10A2 | CHRNB2 973/4885CHRNA4 2055/4885MCHR1 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.